Background
Malignancies represent a persistent burden of morbidity and mortality in people with HIV (PWH). The study aimed to compare cancer-related mortality in PWH with the Italian general population.
Methods
All antiretroviral naïve PWH enrolled in the ICONA cohort (2006-2023) were included. Demographic and clinical characteristics were collected from ICONA database. Deaths caused by cancer (virus-related and non-virus-related) were classified according to ICD-10. The observed death rates in PWH, overall and for cancer, were compared to the ones expected from the general Italian population. Standardized mortality ratios (SMRs) and 95% confidence intervals (95% CI) adjusted by sex, age, and calendar year (2006-2010, 2011-2014, 2015-2018, and 2019-2023) were computed.
Results
14,155 PWH, contributing to 96,488 person-years of follow-up, were enrolled (age 39 y [IQR 31-48], male 81%, Italian origin 75%, MSM 48%, PWID 6.8%). PWH had an excess of all causes (SMR 2.5; 95%CI: 2.4-2.7), as well as cancer-related mortality (SMR 2.21; 95%CI: 1.93-2.52) compared to the general population (Figure 1A). Among virus-related cancers (SMR=11.3; 95%CI: 9.4-13.5), the highest mortality excesses in PWH was for Kaposi’s sarcoma, non-Hodgkin lymphoma, and invasive cervical cancer; among virus-related non-AIDS-defining malignancies, increased mortality was observed for Hodgkin’s lymphoma and anal cancer. Overall, non-virus-related cancers overall did not show an excess of mortality, but significantly higher rates of mortality were observed for cancer of the larynx, lung/trachea/bronchus, bladder, and lymphoid leukaemia. Time trends analysis showed a significant reduction of the risk of all-cause and cancer-related mortality over time, mainly attributable to an important decrease of AIDS-defining malignancies , and a decline of mortality linked to other virus-related cancers, even though an excess of mortality still persists. (Fig 1B).
Conclusions
Although declining since 2006 onward, an elevated risk of death related to cancer (particularly virus-related) persists, as compared to the general population. The crucial role of malignancies as a key cause of morbidity and mortality herein documented underscores the need for enhanced prevention, screening, risk-reduction strategies to mitigate the persistent cancer burden and offer PWH access to the most innovative cancer therapies.
Table or Figure
